Elisa Castaldo’s Post

Can Europe regain its leadership in health and biotech innovation? Absolutely! It begins with reimagining our research ecosystem. On my recent trip to Norway, I met with the Association of the Pharmaceutical Industry (LMI Legemiddelindustrien) and Oslo Science City. We discussed making Europe a center of innovation again, inspired by the Nordic healthcare system, and explored how the Nordic countries can enhance Europe’s healthcare investment landscape. Here are three priorities to bridge the innovation gap with the US and China: 1. Strengthen intellectual property: foster innovation by enhancing IP protection. 2. Develop strategic European policies and collaborations: attract public and private investments through strategic European partnerships. 3. Accelerate market access: recognize the value of new medicines to improve the lives of patients.   By prioritizing innovation, Europe can unlock new opportunities and sustain prosperity. If we can get this right, future generations will benefit from remarkable medical advances and long-term growth. Thanks to Hong Chow , Cathrine M. Lofthus, Ole Petter Ottersen, Idar Kreutzer, Leif Rune Skymoen, Åslaug Helland, Fredrik Schjesvold, Bente Mikkelsen, Christine Wergeland Sørbye, Per Morten Sandset, Ole Alexander Opdalshei, Taher Hassen, Siri Børø, Emilie Wolf Joner

𝗪𝗿𝗮𝗽𝗽𝗶𝗻𝗴 𝗨𝗽 𝗕𝗜𝗢-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 𝗶𝗻 𝗕𝗮𝗿𝗰𝗲𝗹𝗼𝗻𝗮 💼    As we bid farewell to BIO-Europe Spring 2024, let's take a moment to reflect on the lively atmosphere and collaborative spirit that filled the event's halls.    ✨ Facts & Figures ✨    🤝 ~120,000 meeting requests  🤝 ~20,000 meetings  🏢 1,947 companies represented  👥 3,452 delegates attended  💌 MONIPOL prepared ~280 meeting requests and had 25 meetings    These numbers speak volumes about the energy and collaboration present at the event. We were fortunate to connect with many companies interested in exploring our services: throughout the event, we made it a priority to prepare thoroughly and understand our potential clients' needs. This emphasis on research and client-centricity beforehand ensured that meetings were not only productive but also truly beneficial for everyone involved 🤝    𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐦𝐢𝐬𝐬𝐞𝐝 𝐭𝐡𝐞 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐜𝐨𝐧𝐧𝐞𝐜𝐭 𝐰𝐢𝐭𝐡 𝐮𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐞𝐯𝐞𝐧𝐭? Don't worry! Contact us for follow-ups and learn more about how we can support your trials. Let's continue the conversation and explore exciting opportunities at the Virtual Partnering Event, held on 26-27 March 📅     A big thank you to everyone who made BIO-Europe Spring 2024 such a success. We are looking forward to connecting further and supporting innovative biotech pioneers.    Another big thanks to EBD Group for providing a platform to connect the global BioPharma community. We are pleased to have played a part in fostering this vibrant atmosphere.      #BIOEuropeSpring #Biotech #CRO #clinicaltrials #clinicaldevelopment 

Should you attend the upcoming #CEBioForum2024 conference in Warsaw, Poland on March 26-27?  🔔 Consider this: There are over 500 biotech companies in Poland, the Czech Republic, Lithuania, and Estonia combined. That's an impressive number, representing a massive opportunity for collaboration and networking. By attending the conference oragnized by Central European BioForum, you can tap into this potential and form partnerships that could lead to new projects and increased success.  As a #strategic partner of CEBioForum 2024, we invite all European biotech companies to attend the conference and explore the potential for mutual growth and success. Register today and see for yourself why this conference is the place to be for biotech professionals: https://lnkd.in/gmZqfBc2 #centraleurope #biotechindustry #medtech #networking ------------------- We are ExecMind. 🤝 We partner with Life Sciences companies to attract exceptional senior talents and expand their global reach. Would you like to know more about our services? ✚ Follow us on LinkedIn 🔎 Visit our website

The morning after the night before. No, not that one. But the #BIOEurope drinks reception in Stockholm's Nacka Strand Bilfabriken. Thanks again to the excellent EBD Group for hosting another great event. Essential to connect with colleagues and industry partners, and also stay abreast of the latest biopharma thinking in the content sessions. I'm grateful to be able to share the perspectives from Citeline and Evaluate Ltd as part of Monday's industry trends session alongside Isma Hachi, PhD from IQVIA. The ecosystem is navigating funding and productivity challenges to continue to progress a healthy pipeline, although this cannot be taken for granted. Partnerships and deal-making is fundamental to this, but comments from the audience suggest that greater investment and autonomy for the biotech innovators would be welcome. Meanwhile, pharma companies backed by extensive scouting networks and large revenue streams continue to cherry pick treatments with the highest potential. Looking ahead, I'll be discussing some of the major conference themes in a webinar next Thursday (November 14) alongside the in-demand Melanie Senior, who moderated a handful of her own sessions at BIO-Europe. Please do join us - registration is free and available here: https://lnkd.in/e5K5FgqX

Looking forward to this discussion at a critical juncture in translating the potential of Australia's biomedical discoveries and accelerating bio-driven solutions!

So Many Conferences — So Little Time: Which Conference to Visit? I often get asked by companies and industry stakeholders which conferences they should visit or which are worth attending in the first half of the year. I have been in the circle for 25 years now and there is no straight answer. The standard response is, it depends on what you are looking for. If you are looking for general partnering, there are a number of big conferences like the BIO International Convention and "#bioeuropespring", where you can meet people from all over the world. However, there are also some (smaller) regional-focused conferences like the "Swiss Biotech Day #swissbiotechday", which has grown to over 1,800 participants, or the "Asia Bio Partnering Forum #ASIABIO" and BIO KOREA. There are also therapeutic or technology-focused conferences like Advanced Therapies in London, Festival of Biologics in San Diego, or The World Vaccine Congress in DC. If you are fundraising, there are options like the BIO CEO & Investor Conference in NY for more mature (public) companies, "RESI Conferences Life Science Nation (LSN) (Atlanta and Barcelona) for earlier stage (private) companies, as well as LSX World Congress in London or The Annual European Life Sciences CEO Forum #Sachs_ELSF" in Zurich. Additionally, different investment banks host conferences, of which "JPM by JPMorgan Chase & Co." in San Francisco is where the industry meets. For very intimate interactions with other Biotech CEOs, I can recommend the "Biotech CEO Summit CEO Summit by Demy-Colton" in Barcelona and La Jolla. You can find all these conferences, along with their dates and links here https://lnkd.in/dawnkF6p

This year the LSX Nordic Congress is bringing more opportunities than ever before to connect, collaborate, and form lasting relationships with life science innovators and leaders across Northern Europe, as well as international investors! This year's agenda will be looking at the growth and internationalisation of the Nordic region and its transformation into a global hub of innovation. 90+ speakers have already been confirmed including global heads at AstraZeneca, Novo Nordisk, and Genmab and international investors from Forbion, Sunstone Life Science Ventures, and Novo Venture. You can also get involved in: • Networking Drinks: Providing you with the opportunity to informally network and build relationships with key figures in the Northern European life science community • Qualified partnering: Pre-arrange private meetings with your preferred participants ahead of the event with our user-friendly conference partnering platform. Search, filter, and auto-schedule to build your personal itinerary with ease • Showcases: These sessions are designed to highlight Nordic innovation and investment opportunities from across the region. If you're fundraising there's no better place to be, you'll have access to 150+ specialist life science investors Secure the best rate, and book before 28 June to save up to €650. Find out more - https://lnkd.in/eCkHc4Rq #LSXNordic #Biotech #Medtech #healthtech #pharma #investors

Rounding out my recent travels with a stop in beautiful Stockholm 🌍, original home to our regulatory team: NDA Group - an SSI Strategy Company, and this year’s #BIOEurope2024! One topic that has been consistent across recent conferences: the impact of the current funding environment on innovation 📉💡. The industry is on the edge of one of the most significant patent cliffs in history, beginning in 2025. Layering in the Inflation Reduction Act (IRA) and its push to lower drug prices—a vital measure, yet one that raises questions about its influence on innovation and investment in drug discovery. I’d love to hear thoughts from this community on a few specific areas: 1 ) How do you see the IRA affecting funding for innovative therapies? 2) What creative strategies are companies considering to address both the IRA and the upcoming patent cliff? Let’s keep the conversation going in the comments! 💬 Thomas Lönngren Björn Carlsson Arne Saupstad Adriana Valenciano Lena Demetre

ARVOR has been at the forefront of Spanish biotech sector for over 20 years. We specialize in transforming research into reality, guiding you through the intricate landscape of the Spanish market. Here's how we empower your success: - Expert evaluation: We meticulously assess your biotech innovation's commercial potential and market fit within Spain. - Strategic partnering: With our extensive network, we connect you with the ideal investors, industry leaders, and resources to accelerate your progress. - Spanish market navigation: Don't navigate the complexities alone. We'll be your guide, ensuring a smooth and efficient path to market entry. We understand the regulatory issues, market dynamics, and key players in Spain's biotech scene. In addition to evaluation and partnering, ARVOR brings extensive expertise in market analysis, business plan development, partner scouting, and implementation strategies. Book a meeting with us today: https://lnkd.in/dW-sBcJE ➡️ Are you aiming to stablish a robust biotech business in Spain? Let's discuss how ARVOR can turn your vision into reality. #biotech #spain #innovation #partnerships #marketentry #success

Did you know the 𝐔𝐒 𝐧𝐨𝐰 𝐢𝐧𝐯𝐞𝐬𝐭𝐬 €𝟐𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐦𝐨𝐫𝐞 𝐢𝐧 𝐑&𝐃 𝐭𝐡𝐚𝐧 𝐄𝐮𝐫𝐨𝐩𝐞—a leap from just €2 billion in 2002? That’s a staggering 1000% increase! 🚀 Yesterday’s 𝐄𝐅𝐏𝐈𝐀 𝐀𝐧𝐧𝐮𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞, "𝐈𝐌𝐀𝐆𝐈𝐍𝐄 𝐚 𝐡𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫, 𝐦𝐨𝐫𝐞 𝐜𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐄𝐮𝐫𝐨𝐩𝐞,” was a wake-up call. Europe needs to move faster, think bigger, and act bolder to catch up and deliver life-saving innovations to patients who can’t afford to wait. 🕒💡 • 🛠️ What slows down innovation in the EU? • 💰 How can we encourage greater investment by and in Europe? • 📉 Should there be less regulation & stronger IP protection? • 🤖 How can AI revolutionize healthcare & drug development? 3 aspects that struck a chord with me: 🚀 𝐍𝐞𝐞𝐝 𝐟𝐨𝐫 𝐒𝐩𝐞𝐞𝐝 (to borrow from Top Gun): The EU’s drug approval process lags significantly behind the US, disadvantaging European patients who are desperately waiting for new treatment options. Alarmingly, the gap in research and development (R&D) investment is also widening. This highlights the urgency for Europe to address these delays and create a more favorable environment for innovation. 🏛️ 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐚𝐥 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧: The undiscipled discussions among Members of the European Parliament reminiscent of national politics, often reduced the industry's efforts to mere profit-seeking, disregarding the immense risks and substantial investments pharma shoulder in R&D. 📜 𝐈𝐧𝐭𝐞𝐥𝐥𝐞𝐜𝐭𝐮𝐚𝐥 𝐩𝐫𝐨𝐩𝐞𝐫𝐭𝐲 𝐫𝐢𝐠𝐡𝐭𝐬: strong emphasis on the urgent need to strengthen intellectual property rights across the EU, ensuring robust enforcement at the national level to create predictability for innovators. This seems to be a most pressing issue with the new EU pharma legislation. The closing remarks by Lars Fruergaard Jørgensen, EFPIA President & CEO Novo Nordisk, were especially impactful. He reminded us that the 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐝𝐨𝐞𝐬 𝐧𝐨𝐭 𝐬𝐞𝐞𝐤 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐢𝐧𝐜𝐞𝐧𝐭𝐢𝐯𝐞𝐬 𝐛𝐮𝐭 𝐦𝐚𝐫𝐤𝐞𝐭-𝐝𝐫𝐢𝐯𝐞𝐧 𝐨𝐧𝐞𝐬. 𝐀𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐟𝐞𝐰 𝐬𝐞𝐜𝐭𝐨𝐫𝐬 𝐭𝐨 𝐭𝐚𝐤𝐞 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐢𝐬𝐤 𝐨𝐟 𝐬𝐮𝐛𝐬𝐭𝐚𝐧𝐭𝐢𝐚𝐥 𝐮𝐩𝐟𝐫𝐨𝐧𝐭 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬—𝐰𝐢𝐭𝐡 𝐚 𝐡𝐢𝐠𝐡 𝐫𝐢𝐬𝐤 𝐨𝐟 𝐟𝐚𝐢𝐥𝐮𝐫𝐞—𝐢𝐭 𝐢𝐬 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐭𝐨 𝐡𝐚𝐯𝐞 𝐬𝐭𝐫𝐨𝐧𝐠 𝐈𝐏 𝐩𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝐬𝐞𝐜𝐮𝐫𝐞 𝐫𝐞𝐭𝐮𝐫𝐧𝐬 𝐚𝐧𝐝 𝐬𝐮𝐬𝐭𝐚𝐢𝐧 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧. The conference reinforced that collaboration between policymakers and industry leaders is vital. Together, we must drive innovation, accelerate access to treatments, and build a healthier, more competitive Europe. 🔎 It seems most everybody sees the problems and wants to solve them; how to do that still is under discussion. 𝐈 𝐡𝐨𝐩𝐞 𝐰𝐞 𝐝𝐨 𝐧𝐨𝐭 𝐫𝐮𝐧 𝐨𝐮𝐭 𝐨𝐟 𝐭𝐢𝐦𝐞… ⏳ #EFPIA2024 #LifeSciences #PharmaInnovation #FutureOfHealthcare #NeedForSpeed